

**University of Alabama at Birmingham  
School of Medicine Faculty**

**Date: February 2018**

**PERSONAL INFORMATION**

Name: Deniz Peker, M.D.  
Citizenship: Turkey, Permanent Resident (USA)  
Foreign Language(s): Turkish (fluent), Dutch (conversational)  
Home Address: 2492 Magnolia Place, Birmingham, AL 35242  
Phone: 786.219.5074

**RANK/TITLE:**

Associate Professor of Pathology  
UAB Department: Pathology  
Business Address: 1802 6<sup>th</sup> Ave S NP2552 Birmingham, AL 35233  
Phone: 205.934.4555

**HOSPITAL AND OTHER (NON-ACADEMIC) APPOINTMENTS:** (please provide for the past five years)

Attending Pathologist	UAB Hospital	07/12 – Present
Attending Pathologist	UAB Highlands Hospital	07/12 – Present
Consultant Pathologist	Baptist Health System Montgomery, AL	02/14 – Present
Attending Pathologist	Anniston RMC	01/15 - Present

**PROFESSIONAL CONSULTANTSHIPS:**

**EDUCATION:** (please provide for the past five years)

<b>Institution</b>	<b>Degree</b>	<b>Year</b>
Erciyes University	Medical doctor	06/2002

**LICENSURE:**

Florida, ME 132954	2010 – Present
Alabama, MD.31719	2012 – Present

**BOARD CERTIFICATOIN:**

American Board of Pathology, Anatomic and Clinical Pathology	11/21/2010
American Board of Pathology, Hematology	09/26/2012

**POSTDOCTORAL TRAINING:**

<b>Year</b>	<b>Degree</b>	<b>Institution</b>
08/04 – 08/06	AP Residency	University of Istanbul
10/06 – 6/10	AP/CP Residency	Mount Sinai Medical Center
7/10 – 6/12	Hematology Fellowship	Moffitt Cancer Center

**ACADEMIC APPOINTMENTS:**

09/17 – Present	Associate Professor	UAB
07/12 – 08/17	Assistant Professor	UAB
04/17 – Present	Director of Tissue-Based Translational Research Facility	UAB
03/17 – Present	Hematopathology Fellowship Program Director	UAB
07/12 – Present	Associate Professor of Pathology	UAB

09/12 – Present	Co-director, Hematology-Oncology Module	UAB
01/14 – 05/17	Associate Residency Program Director	UAB
12/08 – 04/10	Instructor of Pathology	Barry University School of Podiatry

**AWARDS/HONORS:**

2002	Honors Student Research Award	
2009	Klausner Basic Science Research Award	
2010	Klausner Basic Science Research Award	
2010	Kane Award for Resident of the Year	
2013	Outstanding Teaching Faculty in Laboratory Medicine	
2014	UAB School of Medicine Argus Award Nominee for best MS-2 Organ (Hematology-Oncology)	Module Co-director
2015	UAB School of Medicine Argus Award Nominee for best MS-2 Organ (Hematology-Oncology)	Module Co-director
2016	UAB School of Medicine Argus Award Nominee for best MS-2 Organ (Hematology-Oncology)	Module Co-director
2017	UAB School of Medicine Dean's Excellence Award for Mentorship, Junior Faculty	

**MEMBERSHIPS:**

**PROFESSIONAL SOCIETIES:**

United States and Canadian Academy of Pathology  
 American Society of Clinical Pathology  
 College of American Pathologists  
 American Society of Hematology  
 European Society of Hematology  
 European Society of Pathology

**COUNCILS AND COMMITTEES:**

2008- 2009	Medical Review Committee, Mount Sinai Medical Center
2009- 2010	Cancer Committee, Mount Sinai Medical Center
2010- 2012	Blood Bank Utilization Committee, Moffitt Cancer Center
2013 – Present	Ad Hoc Graduate Faculty Thesis/Dissertation Committee, UAB
2013 - Present	Residency Selection Committee, UAB
2013 – Present	Mentorship Committee Member for: <ul style="list-style-type: none"> <li>- Dr. Sam Borak</li> <li>- Dr. Leona Council</li> <li>- Dr. Frida Rosenblum</li> <li>- Dr. Darrell Sanders</li> </ul>
2014 – Present	Faculty Advisory Council, UAB
2014 – Present	Clinical Competency Committee, UAB
2014 – Present	Residency Program Evaluation Committee, UAB
2014 – Present	Hematopathology Fellowship Program Evaluation Committee UAB
2015 – Present	Dermatopathology Fellowship Program Evaluation Committee UAB
2017 – Present	UAB Research Advisory Committee
2017 – Present	School of Medicine Admission Committee, UAB
2017 – Present	National Comprehensive Cancer Network Acute Myeloid Leukemia Panel

**EDITORIAL BOARD MEMBERSHIPS:**

2014 – Present International Journal of Forensic Science & Pathology  
2016 - Present Clinics in Oncology  
2017 – Present Annals of Blood Cancer  
2018 – Present Editor for Reviews, Lab Medicine

**Peer-Reviewer**

2009 – Present Pathology Research International  
2013 - Present JSM Microbiology  
2014 - Present Cancers  
2015 – Present Southern Medical Journal  
2015 – Present World Journal of Gastroenterology  
2016 – Present Experimental Hematology&Oncology  
2016 – Present Oncotarget  
2016 – Present Blood  
2017 – Present Nature  
2017 – Present European Journal of Haematology

**MAJOR RESEARCH INTERESTS:** (2-3 Sentences)

My primary research is predominantly translational and clinical in hematopathology. The research areas I am interested in include acute and chronic leukemia, including therapy-related forms, primary central nervous system lymphoma and its molecular background, and high grade lymphomas. I also perform translational research on metastatic solid tumors to the brain.

**TEACHING EXPERIENCE:**

12/08 – 04/10 Instructor of Pathology, Barry University, Ft. Lauderdale, FL  
07/12 – Present Anatomic and Clinical Pathology Residency Program, UAB, Birmingham, AL  
09/12 - Present Co-director, Hematology-Oncology Module, UAB, Birmingham, AL  
10/15 Sickle Cell Disease Pathogenesis and Current Guidelines, CME Activity, SMA Annual Assembly, Destin, FL  
04/16 – 09/16 Sickle Cell Disease, Educational Series, Co-Editor of Special Issue (September 2016), CME activity, Southern Medical Journal

**MAJOR INVITED LECTURES AND VISITING PROFESSORSHIPS:**

07/2009 Blood products and blood utilization.  
Mount Sinai Medical Center, Internal Medicine Grand Rounds. Miami, FL  
09/2009 Myeloproliferative Neoplasms, An Update on WHO classifications.  
Mount Sinai Medical Center, Pathology Grand Rounds. Miami, FL  
10/2009 Bleeding Disorders, A Practical Approach to a Bleeding Patient.  
Mount Sinai Medical Center, Pathology Grand Rounds. Miami, FL  
11/2009 Inherited Coagulation Disorders.  
Mount Sinai Medical Center, Pathology Grand Rounds. Miami, FL  
01/2010 Conducting research and basic elements for scientific studies.  
Mount Sinai Medical Center, Surgery Grand Rounds. Miami, FL  
09/2010 Clinical and Laboratory Approach to Bleeding Patient.  
Moffitt Cancer Center, Hematology & Oncology Tuesday Morning Lectures. Tampa, FL  
11/2013 Is chemotherapy a lifesaver or..?  
Sanko University, Medical School, Gaziantep, Turkey  
9/2015 Secondary Malignancies as Complication of Prior Chemo- and Radiation Therapy. 5<sup>th</sup> Cancer Congress, Atlanta, GA  
10/2015 Sickle Cell Disease: Pathophysiologic Concepts and Expert Guidelines for Improved Patient Outcomes. Southern Medical Association Annual Scientific Assembly, Destin, FL  
11/2015 How to Success in Academia as a Junior Faculty. A guidance to the future pathologists. Mount Sinai Medical Center Pathology Grand Rounds

2/2016	Diagnostic Challenges in Histiocytic Neoplasms. Hawaii Society of Pathology, Expert Pathologist Conference Series.
4/2016	Sanko University Medical School Lecture Series as Visiting Professor (4/18/2016-4/23/2016): <ul style="list-style-type: none"> <li>▪ Medical Education in the United States. Past, Present and Future.</li> <li>▪ Personalized Medicine and Its Applications in Cancer.</li> <li>▪ Diagnostic Challenges in Histiocytic Neoplasms.</li> <li>▪ Anemia (Lecture to 2<sup>nd</sup> year medical Students).</li> <li>▪ Hodgkin Lymphomas (Lecture to 2<sup>nd</sup> year medical Students).</li> <li>▪ Gastrointestinal Cancers; Prevention, Diagnosis and Management.</li> </ul>
12/2017	Predictable Future of the Medical Schools and Medical Residency Programs Erciyes University, Kayseri, Turkey
1/2018	A journey to the uncommon hematopoietic lesions University of Pennsylvania Department of Pathology Philadelphia, PA
2/2018	A journey to the uncommon hematopoietic lesions Mount Sinai West Hospital Department of Pathology New York, NY
3/2018	Castleman disease variant POEMS. UAB, Department of Neurology Grand Rounds, Birmingham, AL
3/2018	Emerging biomarkers in diffuse large B-cell lymphoma Mayo Clinic Grand Rounds, Phoenix, AZ

**GRANT SUPPORT: (Past and Current)**

**COMPLETED GRANT SUPPORT**

UAB Center for Metabolic Bone Disease Pilot and Feasibility Grant, Yang Yang – PI; Deniz Peker – Collaborator. This fund was created to investigate the role of myeloma cell-derived RUNX2 in myeloma metastasis to bone (\$30,000).

International Myeloma Foundation Senior Award. Dr. Yang Yang – PI; Deniz Peker – Collaborator. This fund was created to investigate the role of myeloma cell-derived Runx2 in myeloma metastasis: Focus on bone microenvironment (\$80,000).

**ACTIVE GRANT SUPPORT**

International Myeloma Foundation Senior Award. Dr. Yang Yang – PI; Deniz Peker – Collaborator. This fund was created to investigate the role of myeloma cell-derived Runx2 in myeloma metastasis: Focus on bone microenvironment (\$100,000).

UAB Pathology and UAB CCC Neuro-Oncology Pilot Grant Program. Deniz Peker – PI. This fund was created to investigate the role of ZEB2 in solid tumor metastasis to the central nervous system (\$20,000).

UAB Comprehensive Transplant Institute 2015 Angus Cooper Award in Transplant Investigation. Dr. Akinyemi I. Ojesina - P.I. Deniz Peker - Collaborator. This fund was created to investigate potential pathogens in EBV-negative PTLD (\$50,000).

UAB Center for Metabolic Bone Disease Pilot and Feasibility Grant, Yang Yang – PI; Deniz Peker – Collaborator. This fund was created to investigate the role of myeloma cell-derived RUNX2 in myeloma metastasis to bone (\$30,000).

**BIBLIOGRAPHY:**

**MANUSCRIPTS:**

**Manuscripts already published**

1. Akyildiz EU, Peker D, Ilvan S, Calay Z, Cetinaslan I, Oruc. N. Lymphangioma of the ovary: a case report and review of the literature. *J Buon.* 2006;11(1):91-93
2. Setoodeh R, Peker D, Feldman AL, Law ME, Zhang L, Moscinski LC, Shao H. Secondary Hairy Cell Leukemia in a Patient with Chronic Myelogenous Leukemia Following Treatment With Tyrosine Kinase Inhibitors: Report of an Extremely Rare Case and Review of the Literature. *Journal of Medical Cases.* 2012;3(1),39-42
3. Quigley B, Peker D, Zhang L. A composite small lymphocytic lymphoma and Hodgkin transformation presenting as acute appendicitis. *Ann Hematol.* 2012;91(5):801-2
4. Peker D, Alkan S, Zhang L, Martinez A. HIV-associated plasmablastic multicentric Castleman disease with microlymphoma coinfecting with HHV8 and EBV. *J of Hematopathol.* 2012; 6(2),109-114
5. Peker D, Martinez A, Schwartz MA, Cusnir M. Complete remission in 4 patients with human herpes virus-8-associated multicentric Castleman disease using Rituximab and liposomal Doxorubicin, a novel chemotherapy combination. *Clin Adv Hematol Oncol.* 2012;10:204-207.
6. Zhang Y, Zhang L, Jin X, Zhao H, Hao X, Peker D, Wei S, Sokol L, Moscinski L. Bone marrow involvement as initial presentation of CD8 cytotoxic peripheral T-cell lymphoma with CD20 coexpression and relatively indolent clinical course. *Leuk Lymphoma.*2013;54(5),1113-1116.
7. Peker D, Quigley B, Qin D, Papenhausen P, Zhang L. Burkitt Lymphoma Arising From Lymphoplasmacytic Lymphoma Following Acquisition of MYC Translocation and Loss of the ETV6 Tumor Suppressor Gene. *Arch Pathol Lab Med.* 2013;137(1):130-3.
8. Zhou Y, Kraemer RR, Peker D, Wakefield DN, de Idiaquez-Bakula, DA. Novel G377S (c.1246G>T) mutation associated with Gaucher disease type 1. *Am J Hematol.* 2013;88(10):922-923.
9. Brazelton J, Peker D. HIV-related lymphoproliferative disorders. *JSM* 2013;1(1):1005.
10. Brazelton J, Louis P, Sullivan J, Peker D. Temporomandibular joint arthritis as an initial presentation of acute myeloid leukemia with myelodysplasia-related changes: a report of an unusual case. *J Oral Maxillofac Surg.* 2014. Pii:S0278-2391(14)00169-4.
11. Cui X, Peker D, Greer HO, Conner MG, Novak L. Extramedullary hematopoiesis in uterine leiomyoma associated with numerous intravascular thrombi. *Case Rep Pathol.* 2014;2014:957395. Doi: 10.1155/2014/957395. Epub 2014 Mar 6.
12. Paluri R, Nabell L, Borak S, Peker, D. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review. *Hematol Oncol.* 2015 Dec;33(4):206-11.
13. Matnani R, Peker D. Azathioprine induced Epstein Barr virus-positive mucocutaneous ulcer arising in perianal fistula and abscess associated with Crohn's disease. *J Crohns Colitis.* 2014 Dec 1;8(12):1747-8
14. Peker D, Parekh V, Paluri R, Deal T, Borate U, Harada S, Agosto-Arroyo E, Reddy V. Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: A single institution experience. *International Journal of Hematology.* 2014 Nov;100(5):457-63
15. Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution. *Acta Haematol.* 2014 Nov 20;133(2):249-256
16. Ma Y, Wei S, Peker D. Primary Gallbladder Myxoid Liposarcoma Associated with Amplification of CHOP Gene: Presentation of an Extremely Rare Case. *J Gastrointest Liver Dis.* 2014 Dec;23(4):460-1.
17. Parekh V, Peker D. Malignant Transformation in Von Meyenburg Complexes: Histologic and Immunohistochemical Clues with Illustrative Cases. *Appl Immunohistochem Mol Morphol.*2015 Mar 16. [Epub ahead of print]
18. Trotter TN, Li M, Pan Q, Peker D, Rowan PD, Li J, Zhan F, Suva LJ, Javed A, Yang Y. Myeloma cell-derived Runx2 promotes myeloma progression in bone. *Blood.* 2015 Jun 4;125(23):3598-608.
19. Koenig G, Stevens T, Peker D. Plasmablastic microlymphoma arising in HHV8- associated multicentric Castleman disease in HIV-seronegative patient with clinical response to anti-IL-6 therapy. *Histopathology.* 2015 Dec;67(6):930-2
20. Parekh V, Peker D. EBV-related primary splenic lymphocyte-depleted classical Hodgkin lymphoma. *J Clin Pathol.* 2015 Nov;68(11):947-50
21. Matnani R, Parekh V, Borate U, Brazelton J, Reddy V, Peker D. Therapy-related B-lymphoblastic leukemia associated with Philadelphia chromosome and MLL rearrangement: Single institution

- experience and the review of the literature. *Pathol Int*. 2015 Aug 11. doi: 10.1111/pin.12337. [Epub ahead of print]
22. Wu X, Lee J, Peker D, Spitzer S, Laser J, Reddy V, Harada S. Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant? – Multi-Institutional Study. *Appl Immunohistochem Mol Morphol*. 2015 Sep 14. [Epub ahead of print]
  23. Parekh V, Peker D. Clinicopathologic and Cytogenetic Characterization of Therapy-related Acute T Lymphoblastic Leukemia in Adult Population. *Leuk Lymphoma*. 2015 Nov 20:1-3. [Epub ahead of print]
  24. Li J, Pan Q, Rowan PD, Trotter TN, Peker D, Regal KM, Javed A, Suva LJ, Yang Y. Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. *Oncotarget*. 2016 Feb 3. doi: 10.18632/oncotarget.7170. [Epub ahead of print].
  25. Guthrie PJ, Thomas JV, Peker D, Turkbey B, Rais-Bahrami S. Perivesicle unicentric Castleman disease initially suspected to be metastatic prostate cancer. *Urol Annals*. 2016Apr8(2):245-248.
  26. Soni A, Paluri R, Peker D. Extramedullary Manifestations of CML. A Case Series of Clinicopathological and Molecular Features. *J Clin Med Res*. 2016;8(6):480-485.
  27. Duncan VE, Ping Z, Varambally S, Peker D. Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2016 May 17:1-6
  28. Stewart R, Peker D. Preface. Special Issue on Sickle Cell Disease. *South Med J*. 2016 Sep;109(9):494.
  29. Trotter TN, Sherpa TL, Gibson J, Pramod GS, Peker D, Yang Y. Adipocyte-lineage cells support growth and dissemination of multiple myeloma in bone. *Am J Pathol*. 2016 Sep 17. pii: S0002-9440(16)30292-9.
  30. Costa LJ, Maddocks K, Epperla N, Reddy N. et al. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. *Am J Hematol*. 2017 Feb;92(2):161-170. doi: 10.1002/ajh.24615.
  31. Tracht J, Zhang K, Peker D. Grading and prognostication of neuroendocrine tumors of the pancreas: A comparison study of Ki67 and PHH3. *J Histochem Cytochem*. 2017 Jul;65(7):399-405.
  32. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, et al. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2017 Jul;15(7):926-957
  33. Ullman D, Baumgartner E, Whukowski N, Koenig G, Mikhail FM, Pavlidakey P, Peker D. Therapy-associated myelodysplastic syndrome with monosomy 7 arising in a Muir-Torre Syndrome patient carrying SETBP1 mutation. *Mol Clin Oncol*. 2018 Feb;8(2):306-309
  34. Broadwater DR, Peker D. Systemic Non-Hodgkin T Cell Lymphomas Presenting in the Head and Neck Region: An Institutional Experience of a Rare Entity. *Head Neck Pathol*. 2018 Jan 4. doi: 10.1007/s12105-017-0881-3. [Epub ahead of print].

#### **In Press:**

#### **Under evaluation**

1. Agosto-Arroyo E, Harada S, Williams L, Yang Y, Vicinanzo M, Peker D. MYC/IgH translocation associated transformation of extranodal marginal zone lymphoma of ocular adnexa to high grade diffuse large B-cell lymphoma. Molecular analysis of a rare entity. Submitted to *Hematol Oncol*.
2. Broadwater D, Peker D. Systemic non-Hodgkin T-cell Lymphomas primary to head and neck region. An institutional experience of a rare entity. Submitted to *Journal of Head&Neck Pathology*

#### **In preparation**

1. Peker D, Matnani R, Houldsworth J, Ma C, Hooper K, Hackney R, Siegal G. Molecular Karyotypic Features of Primary Central Nervous System Lymphoma.
2. Peker D, Lazenby AJ, Heslin MJ, Marques M. Acquired hemophilia Associated with IgG4-related autoimmune sclerosing cholangitis. Submitted to *Hemophilia*

#### **BOOKS:**

Books and Book Chapters

1. Molecular pathology and Diagnostics of Cancer (Cancer growth and Progression). Dominico Coppola (Editor). Chapter 17 Molecular diagnostics of lymphoid neoplasms. Peker D, Jiaungo T, Zhang L. Springer 2013. p521-556.
2. Nonneoplastic Hematopathology and Infections. Hernani Cualing, MD (Editor) Chapter 10 Hematologic Aspects of Tropical Infections- Anemias, Purpuras and Thrombopathy In The Tropics. Peker D. Wiley-Blackwell. 2012. p195-205

**ABSTRACTS:**

1. Peker D, Willis I, Saiz E. Primary schwannoma of lymph node in the retroperitoneal region. *Virchows Archiv.* 2007;451(2):580-580.
2. Peker D, Poppiti RJ, Alexis J, Howard L, Saiz E, Yaziji H. Refining the diagnostic approach in the evaluation of HER2 in breast cancer: A survey of 2008 invasive breast cancers comparing a rabbit polyclonal antibody, rabbit monoclonal antibody with fluorescence in situ hybridization. *Laboratory Investigation.* 2009;89:63A-63A
3. Peker D, Chang CC, Hagemester C, Zu Y, Ewton A, Curry C, Jones D. Strong expression of D2-40 in lymphoma-associated stroma is associated with superior outcome in diffuse large B-cell lymphoma. *Laboratory Investigation.* 2009;89:280A-280A.
4. Peker D, Poppiti RJ, Yaziji H, Martinez A. Frequent Coexpression of HHV-8 and EBV in HIV-Associated Multicentric Castleman Disease. *Laboratory Investigation.* 2010;90:316A-316A.
5. Quigley B, Peker D, Zhang L. A composite small lymphocytic lymphoma and Hodgkin transformation presenting as acute appendicitis. *Annals of Hematology.* 2011:1-2.
6. Zhang X, Moscinski L, Bennett JM, Setoodeh R, Peker D, Zhang L. Morphologic and Phenotypic Features of Concurrent Clonal T-Cell Large Granular Lymphocytic Expansion and Myelodysplastic Syndrome. *Blood.* 2011;118(21):1209-1209.
7. Peker D, Moscinski L, Mathew R, Zhang L. Paraneoplastic Skin Findings in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. *Laboratory Investigation.* 2012;92:360A-361A.
8. Zhang X, Moscinski L, Setoodeh R, Peker D, Zhang L. Detection of Clonal T-Cell Large Granular Lymphocytes in Low-Grade Myelodysplastic Syndrome. *Laboratory Investigation.* 2012;92:384A-384A.
9. Kubal TE, Peker D, Sagatys E, Zhang L, Nagashpour M, Moscinski L, et al. Natural history and clinical prognosis of in situ mantle cell lymphoma. *J Clin Oncol.* 2012;30(15).
10. Jaglal M, Peker D, Bello CM, Shah BD, et al. A review of clinicopathologic characteristics, therapy, and outcomes of 22 patients with aggressive B-cell lymphoma. *J Clin Oncol.* 2012;30(15).
11. Peker D, Kubal TE, Sotomayor EM, Sokol L, et al. Unusual primary presentations of mantle cell lymphoma in the urinary tract and testes. *J Clin Oncol.* 2012;30(15).
12. Peker D, Liu J, Padron E, Lancet J, et al. P-130 Reticulin fibrosis in disease progression and overall survival of chronic myelomonocytic leukemia: An independent prognostic factor? *Leuk Research.* 2013;37(supplement 1).
13. Deal T, Borate U, Harada S, Reddy V, Peker D. Therapy-Related Myeloid Sarcoma As a New Diagnostic Entity? A 10-Year Institutional Retrospective Review. *Blood.* 2013;122(21):2656-2656.
14. Deal T, Brazelton JD, Harada S, Borate U, Reddy V, Peker D. Clinicopathological and Molecular Features of Treatment-Related Myeloid Sarcoma, a Subtype of Treatment-Related Myeloid Neoplasms. *Laboratory Investigation.* 2014;94:344A-345A.
15. Brazelton JD, Deal TM, Peker D. Does Frequent Expression of CD200 in Adult B-Lymphoblastic Lymphoma Have a Prognostic Value? An Institutional Survival Analysis. *Laboratory Investigation.* 2014;94:338A-338A.
16. Li M, Trotter TN, Peker D, Dowan PD, Qianying P, Suva LJ, Javed A, Yang Y. Myeloma Cell-Derived Runx2 Promotes Myeloma Progression and Bone-Homing. *Blood.* 124 (21), 724-724.
17. Qianying P, Dowan PD, Innis-Shelton R, Trotter TN, Li M, Peker D, Suva LJ, Yang Y. Heparanase Promotes Myeloma Metastasis By Inducing EMT-like Features in Both Myeloma Cells and Endothelial Cells. *Blood.* 124 (21), 2025-2025.
18. Cinar M, Peker D, Altyurek N, Huang Q, Lopategui J, Cinar B, Alkan S. Analysis of Aurora Kinase A and B in Double Hit and Triple Hit Lymphomas. *Laboratory Investigation.* 95, 340A-340A.

19. Peker D, Matnani R, Houldsworth J, Hackney JR. Molecular Cytogenetic Features of Primary Central Nervous System Lymphoma. *Laboratory Investigation*. 95, 371A-371A.
20. Rosenblum F, Parekh V, Reddy V, Peker D. Therapy-related acute myeloid leukemia in adults: is age younger than 40 clinically relevant? *Haematologica*.2015/6/1;376-376
21. Wu X, Lee JW, Peker D, Spitzer SG, Laser J, Reddy VV, Harada S. *Appl Immunohistochem Mol Morphol*. 2015/9
22. Dai Q, Harada S, Peker D. Prognostication of High-Grade Diffuse Large B-Cell Lymphoma and the Role of MYC, BCL2, and Phosphohistone H3. *Am J Clin Pathol*. Volume 144, Issue suppl 2, 1 October 2015
23. Borate U, Hathaway AR, Peker D, Jackson BE, Kota VK, Shah BD, Zhang L, Jillella D, Arellano M, Heffner LT, Erba HP. Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review. *Blood*.2015;126(23):4869-4869
24. Shah BD, Borate U, Kota VK, Zhang L, Peker D, Hathaway AR, Chavez JC. Multi-Institution Review of Adult Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL). *Blood*.2015;126(23):3715-3715
25. Kota VK, Hathaway AR, Shah BD, Peker D, Zhang L, Jaye DL, Arellano M, Khoury HJ, Jillella AP, Winton EF, Heffner LT, Borate U. Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma. *Blood*.2015;126(23)
26. Trotter TN, Lama-Sherpa TD, Peker D, Javed A, Suva LJ, Yang Y. The Role of Adipocyte Lineage Cells in Myeloma Growth and Dissemination in Bone. *Blood*. 2015;126 (23):1797-1797
27. Borate U, Peker D, Foran JM, Costa LJ. Differences in Cell of Origin (COO) Affect Outcomes in Caucasian (C) but Not in African American (AA) Patients with Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*. 2015;126 (23)
28. Peker D, Jamil MO, Salzman D, Jackson BE, Borate U. Outcomes of Allogeneic Stem Cell Transplantation (alloSCT) for Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Biology of Blood and Marrow Transplantation*. 2016;3(22):S346-S347
29. Duncan VE, Varambally S, Peker D. RUNX3: A New Prognostic Marker in Diffuse Large B-Cell Lymphoma? *LABORATORY INVESTIGATION*. 2016;96:342A-342A
30. Hathaway AR, Peker D, Bradford EJ, Vamsi KK, Shah BD, Zhang L, Jillella AP, Arellano M, Heffner LT, Erba HP, Borate U. Early Allogeneic Stem Cell Transplantation Appears to Improve Outcomes in Adult T-cell Acute Lymphoblastic Lymphoma/Leukemia (T-ALL/T-LBL) Patients: Multi-Institutional Review. *Biology of Blood and Marrow Transplantation* 22 (3), S202
31. Duncan V, Peker D. The Role of RUNX3 in Colorectal Cancer. *American Journal of Clinical Pathology* 146 (suppl 1), 291
32. Peker D, Chakravarthi B, Siegal G, Varambally S, Harada S. Down-regulation of RUNX3 expression in solid tumor metastatic to the brain. *Virchows Archiv* 469, S205-S205.
33. Osteocyte Apoptosis Attracts Myeloma Cells to Bone and Supports Progression through Regulation of the Bone Marrow Microenvironment. Trotter TN, Fok M, Gibson JT, Peker D, Javed A, Yang Y. *Blood* 128(22),484-484
34. Kami J Maddocks, Narendranath Epperla, Julio C Chavez, Nishitha Reddy, Reem Karmali, Elvira Umyarova, Cristiana A Costa, Veronika Bachanova, Martha Glenn, Oscar Calzada, Ana Xavier, Zheng Zhou, Nasheed Mohammad Hossain, Francisco J Hernandez-Ilizaliturri, Zeina Al-Mansour, Stefan Klaus Barta, Saurabh Chhabra, Frederick Lansigan, Amitkumar Mehta, Michael V Jaglal, Andrew Evans, Deniz Peker, Andre Forero-Torres, Christopher Flowers, Timothy S Fenske, Jonathon B Cohen, Mehdi Hamadani, Luciano J Costa. Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. *Blood* 128 (22), 103-103



35. Gibson B, Matnani R, Ping Z, Chakravarthi BSK, Yang Y, VArambally S, Peker D. Increased expression of EZH2 is Associated with Inferior Survival in Parimary Central Nervous System Diffuse Large B-Cell Lymphoma. *Blood*.128(22)4216-4216
36. Peker D, Roma-Holba S, Kwon Y, Gordetsky J, Mehta A, Forero A, Costa LJ, Reddy Vishnu, Yang Y, Charavarthi BVSK, Varambally , EZH2 Upregulation is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoa through Potential RUNX3 Downregulation. *Blood*.128(22)5301-5301

**POSTER EXHIBITS:**

1. Peker D, Jijun I, Zhang L. Reticulin fibrosis in disease progression and overall survival of chronic myelomonocytic leukemia: an independent prognostic factor. American Society of Clinical Pathology Annual Meeting, Las Vegas, NV. October 2011.
2. Padron E, Al-Ali N, Peker D, Lancet JE, et al. Hypomethylating Agents Improve Overall Survival in Higher Risk Chronic Myelomonocytic Leukemia (CMML). ASH Annual Meeting, Atlanta, GA, December, 2012.
3. Padron E, Al-Ali N, Peker D, Lancet JE, et al. A Comparison of Prognostic Models for Chronic Myelomonocytic Leukemia (CMML) in the Era of Hypomethylating Agents. ASH Annual Meeting, Atlanta, GA, December, 2012.
4. Peker D, Pardon E, Horna P, Bennet JM, et al. A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML). ASH Annual Meeting, Atlanta, GA, December, 2012.
5. Surowiecka M, Peker D, Kang L. Composite low grade follicular lymphoma and nodular lymphocyte predominance Hodgkin lymphoma. A case report. College of American Pathologists Annual Meeting, Dallas, TX. September, 2011.
6. Peker D, Sagatys E, Quigley B, Moscinski L, Zhang L. Leptomeningeal Relapse After Stem Cell Transplant in Plasma Cell Neoplasms Including Plasma Cell Leukemia: A Report of 2 Cases. College of American Pathologists Annual Meeting, Dallas, TX. September, 2011.
7. Cui X, Peker D, Novak L. Leiomyoma with extramedullary hematopoiesis and intravascular thrombosis. ASCP Annual Meeting, Chicago, IL. September, 2013.
8. Parekh V, Reddy S, Peker D. Histologic Glimpse to Cholangiocarcinoma Arising in Von-Meyenburg Complexes: Report of a Rare Case. ASCP Annual Meeting, Chicago, IL. September, 2013.
9. Deal D, Stevens T, Peker D. CD20-negative B-cell lymphoma of the tongue: report of an unusual case. College of American Pathologists Annual Meeting, Orlando, FL. October, 2013.
10. Zu J, Peker D. Posttransplant Lymphoproliferative Disorder Occuring in a Heart Allograft. College of American Pathologists Annual Meeting, Orlando, FL. October, 2013.
11. Zhou Y, Wakefield D, Peker D. New Diagnosis of Gaucher's Disease and Monoclonal Gammopathy in a 61 Year-Old Man. College of American Pathologists Annual Meeting. Orlando, FL. October, 2013.
12. Brazelton B, Reddy V, Peker D. AML with recurrent genetic mutations. Society for Hematopathology/European Association for Haematopathology 2013 Workshop, Houston, TX. October, 2013.
13. Borak S, Reddy V, Peker D. Extramedullary manifestations of myeloid neoplasms. Society for Hematopathology/European Association for Haematopathology 2013 Workshop, Houston, TX. October, 2013.
14. Arroyo EA, Harada S, Peker D. Transformation Of Extranodal Marginal Zone Lymphoma Of Mucosa-associated Lymphoid Tissue Lymphoma Into Diffuse Large B-cell Lymphoma Associated With Myc Rearrangement. CAP Annual Meeting. Chicago, IL. September 2014.
15. Parekh V, Peker D. Littoral-cell angioma presenting as spontaneous splenic rupture: Report of a rare case. ASCP Annual Meeting. Tampa, FL. October 2014
16. Soni A, Peker D. Extramedullary blast crisis in chronic myelogenous leukemia. A case series of unusual clinicopatholgoical features. ASCP Annual Meeting. Tampa, FL. October 2014

17. Koenig G, Reddy V, Peker D. Transformation of chronic eosinophilic leukemia into acute myeloid leukemia presenting as myeloid sarcoma. ASCP Annual Meeting. Tampa, FL. October 2014
18. Trotter TN, Peker D., Rowan PD, Pan Q, Li M., Yang Y. Pre-adipocyte secreted factors promote myeloma motility and progression. UAB CCC Retreat. Birmingham, AL. October, 2014.
19. Pan Q, Rowan PD, Innis-Shelton RD, Trotter TN, Li M., Peker D., Suva LJ, Yang Y. Heparanase promotes myeloma metastasis by inducing EMT-like features in both myeloma cells and endothelial cells. 56th Annual Meeting of American Society of Hematology. San Francisco, CA. December, 2014.
20. Li, M., Trotter, T.N., Peker, D., Rowan, P.D., Pan, Q., Suva, L.J., Javed, A., and Yang, Y. Myeloma cell-derived Runx2 promotes myeloma progression and bone-homing. 56th Annual Meeting of American Society of Hematology. San Francisco, CA. December, 2014.
21. Peker D, Matnani R, Dai Q, Houldsworth J, Ma C, Hackney J. Molecular Cytogenetic Features of Primary Central Nervous System Lymphomas. USCAP Annual Meeting, Boston, MA. March, 2015.
22. Rosenblum F, Parekh V, Reddy V, Peker D. Therapy-related acute myeloid leukemia in adults: is age younger than 40 clinically relevant? *Haematologica*.2015/6/1;376-376
23. Tracht Jessica, Zhang Kui, Peker D. The Role of Ki-67 and PHH-3 in Grading and Prognostication of Pancreatic Neuroendocrine Tumors: A Comparison Study. CAP Annual Meeting, Nashville, TN. October, 2015.
24. Parekh V, Peker D. Therapy-Related Acute T Lymphoblastic Leukemia: Report of 2 Cases. CAP Annual Meeting, Nashville, TN. October, 2015.
25. Dai Q, Harada S, Peker D. Prognostication of high grade diffuse large B-cell lymphoma and the role of MYC, BCL2, and PHH3. ASCP Annual Meeting, Long Beach, CA. October, 2015.
26. Wu X, Lee JW, Peker D, Spitzer SG, Laser J, Reddy VV, Harada S. ASCP Annual Meeting, Long Beach, CA. October, 2015.
27. Borate U, Hathaway AR, Peker D, Jackson BE, Kota VK, Shah BD, Zhang L, Jillella D, Arellano M, Heffner LT, Erba HP. Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review. American Society of Hematology Annual Meeting. Orlando, FL. December 2015.
28. Shah BD, Borate U, Kota VK, Zhang L, Peker D, Hathaway AR, Chavez JC. Multi-Institution Review of Adult Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL). American Society of Hematology Annual Meeting. Orlando, FL. December 2015.
29. Kota VK, Hathaway AR, Shah BD, Peker D, Zhang L, Jaye DL, Arellano M, Khoury HJ, Jillella AP, Winton EF, Heffner LT, Borate U. Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma. American Society of Hematology Annual Meeting. Orlando, FL. December 2015.
30. Trotter TN, Lama-Sherpa TD, Peker D, Javed A, Suva LJ, Yang Y. The Role of Adipocyte Lineage Cells in Myeloma Growth and Dissemination in Bone. American Society of Hematology Annual Meeting. Orlando, FL. December 2015.
31. Borate U, Peker D, Foran JM, Costa LJ. Differences in Cell of Origin (COO) Affect Outcomes in Caucasian (C) but Not in African American (AA) Patients with Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*. 2015;126 (23)
32. Peker D, Jamil MO, Salzman D, Jackson BE, Borate U. Outcomes of Allogeneic Stem Cell Transplantation (alloSCT) for Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome. BMT Tandem Meeting. Honolulu, HI. February, 2016.
33. Duncan VE, Varambally S, Peker D. RUNX3: A New Prognostic Marker in Diffuse Large B-Cell Lymphoma? USCAP Annual Meeting. Seattle, WA. March, 2016.

#### **ORAL PRESENTATIONS:**

##### **Scientific papers presented at national and international meetings**

1. Frequent co-expression of HHV-8 and EBV in HIV-associated multicentric Castleman disease. United States and Canadian Academy of Pathology Annual Meeting, Washington, DC. March, 2010
2. Microlymphoma Arising in a HIV+ with HHV8+ EBV+ Multicentric Castleman Disease. European Association of Haematopathology Annual Meeting, Upsala, Sweden. October, 2010.

3. Adult T cell lymphoma. Society of Hematopathology/European Association of Hematopathology Workshop, Los Angeles, CA. October, 2011
4. Primary cutaneous gamma-delta T-cell lymphoma. European Association of Hematopathology Workshop, Lisbon, Portugal. October, 2012.